Citations

Institution: Mayo Clinic Clear

Showing 10 of 108104 citations.

Stroke in the Young: A Case of CNS Vasculitis Secondary to Systemic Lupus Erythematosus
Badir, John , Thorson, Justin, Barr, Emily , Ranasinghe, Tamra

Clinical Case Reports | July 8, 2025 | Volume: 13 | Issue: 7 | Pages: No page available

10.1002/ccr3.70606 | PMID 40630753 Get It

ABSTRACT Systemic lupus erythematosus (SLE) is an enigmatic autoimmune disease with a varied presentation that carries with it an increased risk for many potentially life‐threatening problems. When compared with the general population, the relative risk of ischemic stroke in SLE is more than doubled. Our case report highlights a rare complication of SLE, vasculitis as the cause of stroke. CNS vasculitis secondary to SLE most commonly affects the endothelium of small and medium vessel arteries through perivascular inflammation in a concentric pattern. We present a case of a 46‐year‐old female with a history of hypertension, hyperlipidemia, hypothyroidism, multiple ischemic strokes (residual left sided weakness), and elevated cardiolipin IgM levels (not on anticoagulation) who presented with left facial numbness, dysarthria, and word finding difficulty. The initial CT head revealed chronic appearing hypodensities in the right parietal and occipital lobes without hemorrhage. CT angiogram of the head and neck demonstrated multifocal stenosis in the right MCA and right PCA. She received IV tenecteplase and MRI brain revealed an infarct in the left MCA distribution along with infarcts in the right thalamus, hippocampus, and cerebellum. Transesophageal echocardiogram was negative for Libman‐Sacks endocarditis. Given concerns for an underlying vasculitis process, an MRA vessel wall imaging was obtained which demonstrated concentric enhancement and persistent vessel narrowing in the left MCA M2 along with symmetric concentric enhancement of vaso vasorum of intracranial vertebral arteries. Lumbar puncture revealed CSF protein 60, culture negative, glucose 61, white blood cells 3, IgG index 0.5, ACE negative, and no oligoclonal bands. Her ESR was 43 and CRP < 0.5. Hypercoagulability workup demonstrated RNP > 8, SSA 6.4, Smith 1.6, +ANA 1:1280, C4 11, cardiolipin IgM 60. Given serum ANA titers and anti‐cardiolipin IgM labs in the setting of intracranial vessel wall enhancement concerning for an inflammatory process, it was believed that this stroke was actually a result of lupus vasculitis. The paucity of literature on the association between SLE vasculitis and cerebrovascular disease presents an important opportunity for more research, and it may be prudent to further investigate the relative risk of stroke in patients with known SLE vasculitis. This is also important because young individuals with SLE are at a higher relative risk of stroke.
Bilateral Kienböck Disease: Associations With Demographic, Systemic, and Radiologic Findings
Emanuels, Andrew, Rames, Jess D. , Tunaboylu, Mehmet Furkan , Moran, Steve, Emanuels, Andrew F., Rames, Jess, Moran, Steven L

HAND | July 8, 2025 | Volume: 21 | Issue: 5 | Pages: 772-777

10.1177/15589447251350174 | PMID 40624876 Get It

Background: Kienböck disease most frequently affects 1 wrist and rarely occurs bilaterally. The purpose of this study is to describe the natural history and identify risk factors for development of bilateral Kienböck disease. Methods: After institutional review board approval, 350 patients with surgically managed Kienböck disease from 1976 to 2023 were identified. A retrospective review of the electronic medical record was used to collect demographic, clinical, and radiographic information. Two-tailed student t -test was used for continuous variable, and Fisher’s exact test was used for categorical variables with analysis of power. Results: Ten of 350 patients (2.9%) had bilateral disease. The mean age was 45 (range: 14-62) years, and 6 out of 10 patients were female. The mean follow-up time was 47 (range: 9-274) months. Three of the 10 patients were laborers. Antecedent trauma (n = 2), prior corticosteroid injection (n = 1), and concomitant autoimmune disease (n = 1) were rare events. There was no difference in Lichtman Stage comparing the dominant and nondominant hands, and 72.2% of wrists were ulnar negative. This was higher but not significantly different than the unilateral affected comparison cohort (60%). Sufficient power was demonstrated (0.99). Eighteen of 20 wrists were treated operatively. Two cases required operative revision due to progression of disease. Conclusions: The cause of bilateral versus unilateral Kienböck disease remains unclear. Bilateral disease was not associated with a higher incidence of autoimmune disease, systemic corticosteroid use, or exposure to heavy manual labor. However, thrombosis leading to avascular necrosis of the lunate may be influenced by hypercoagulable and inflammatory diseases. Surgeons should maintain a high index of suspicion for bilateral disease in patients with these comorbidities. Routine screening of the contralateral wrist is unjustified if the patient is asymptomatic.
Hepatic Cytochrome P450 Enzymatic System Interaction With Platelet Function and Cardiovascular Outcomes—Pharmacogenomic Impact on Inter‐Organ Communication
Figueiral, Marta , Castrichini, Matteo , Pruthi, Rajiv K. , Pereira, Naveen L. , Al-Abcha, Abdullah, Castrichini, Matteo , Al‐Abcha, Abdullah

Comprehensive Physiology | July 8, 2025 | Volume: 15 | Issue: 4 | Pages: No page available

10.1002/cph4.70027 | PMID 40624767 Get It

ABSTRACTPlatelets are small, anucleate particles derived from bone marrow megakaryocytes that circulate in the blood and are central to hemostasis, atherothrombosis, and post‐angioplasty coronary restenosis. Initially thought to involve a simple process of platelet adhesion, activation, and aggregation, recent insights reveal an important interplay with genetics and other organ systems, especially in the setting of antiplatelet drug therapy. Interaction involving the hepatic cytochrome P450 enzymes, which regulate drug metabolism, and genetic variation in those enzymes affecting drug response, underscores the liver's role in modulating platelet function by attenuating circulating active drug metabolites with eventual cardiovascular implications. Circulating adhesive proteins such as von Willebrand Factor and fibronectin also significantly regulate platelet aggregation, a process that is further influenced by varying shear conditions within the vascular system. The efficacy of antiplatelet therapies can be attenuated by such individual genetic variation, which can affect multiple cellular pathways involved not only in drug metabolism and clearance but also the drug target itself. Identifying these genetic differences allows for tailored therapy, enhancing treatment outcomes and minimizing adverse effects. Genetic variation, particularly in the CYP2C19 gene, influences individual responses to the most commonly used antiplatelet drug other than aspirin, clopidogrel, with certain variants leading to reduced drug metabolism and antiplatelet effects. Therefore, genotype‐guided antiplatelet therapy has emerged as a promising approach to reduce ischemic events and minimize bleeding events. This personalized strategy requires an understanding of genetic variation, drug‐gene interaction, and the liver's role in impacting platelet function, the coagulation system, and cardiovascular systems.
Characteristics of High-Performing Administrative Leaders in a Physician-Administrator Dyad in an Academic Medical Center
Kang, Ji Yun, Huang, Yu-Li , Lee, Minji , Cerri, Petrine , Klavetter, Eric

Journal of Healthcare Management | July 7, 2025 | Volume: 70 | Issue: 4 | Pages: 288-302

10.1097/jhm-d-24-00157 | PMID 40623225 Get It

Goal: The purpose of the research is to explore, through the lens of organizational performance and staff satisfaction, the characteristics of administrative leaders working as dyad partners with physician leaders. Methods: All 54 administrative leaders from 71 clinical departments at the three US Mayo Clinic sites were invited to participate in the study. We used an unsupervised cluster analysis machine learning method to group the leaders based on their characteristics, as measured by the 32-dimension Occupational Personality Questionnaire (OPQ 32r), and we used a three-cluster model to explore the relationships between the clusters and the performance outcome. We took the department performance data from the previous year and compared the percentage of departments with the upward changes among the clusters. For staff survey data, we calculated the percentage of departments with scores that were above average among the three clusters for both physician and administrative staff responses. Principal Findings: Analysis of personality data revealed three different clusters. Cluster 1 leaders were caring and democratic, forward-thinking, strategic, optimistic, and trusting of others. Cluster 2 leaders were extremely hardworking and authoritative. Cluster 3 leaders were caring, modest, and rule-following. Cluster 1 leaders showed the best financial performance and sense of belonging among their followers, cluster 2 leaders elicited high engagement from their departments, and cluster 3 leaders encouraged lower burnout among staff members. Practical Applications: From this study, we obtained empirical evidence of administrative leaders’ characteristics that showed positive relationships with financial and staff-satisfaction metrics. The results showed that distinct types of leaders influence administrative staff and physician staff differently and that different situations require different styles of leadership. We can also conclude that implementing robust, scientifically validated tools to assess leadership traits and tendencies can positively affect leadership and organizational performance for healthcare organizations.
Days at Home Up to 30 Days After Robotic Versus Laparoscopic Colorectal Surgery
Wickramasinghe, Shehan , Klein, Kerenaftali, Pornkul, Panuwat , Mushaya, Chrispen, Larson, David W., Wickramasinghe, Shehan S , Larson, David W., Sakata, Shinichiro

Diseases of the Colon & Rectum | July 7, 2025 | Volume: 68 | Issue: 10 | Pages: 1207-1214

10.1097/dcr.0000000000003861 | PMID 40623210 Get It

BACKGROUND: “Days at home up to 30 days” is a novel patient-centered outcome metric that measures the number of days patients spend at home 30 days after surgery. It encompasses inpatient stay from index admission, interhospital transfers and step-downs, and readmissions across different hospitals. OBJECTIVE: Comparison of days at home up to 30 days and established outcome metrics after robotic versus 3-dimensional laparoscopic colorectal surgery. DESIGN: Prospective cohort study of consecutive patients. SETTING: Townsville University Hospital and Mater Private Hospital, Townsville, Queensland, Australia. PATIENTS: Adult patients undergoing robotic and 3-dimensional laparoscopic colorectal surgery. MAIN OUTCOME MEASURES: Days at home up to 30 days, 30-day readmission rate, index admission length, and 30-day postoperative complication rates. RESULTS: Of 82 patients, 32 (39%) underwent robotic and 50 (61%) underwent 3-dimensional laparoscopic colorectal surgery. Robotic ultralow and low anterior resection, as well as abdominoperineal resection, resulted in significantly more days at home (23 vs 15 days at home, p = 0.05) and a shorter length of index admission (7 vs 15 days in hospital, p = 0.0003). However, there was no significant difference in major postoperative complications and 30-day readmission rate. No significant differences were found between robotic and 3-dimensional laparoscopic right hemicolectomy or high anterior resection. LIMITATIONS: Unrandomized study. Patient selection for robotic and 3-dimensional laparoscopic surgery was at the surgeons’ discretion. CONCLUSIONS: Patients undergoing robotic ultralow and low anterior resection, as well as abdominoperineal resection, spent more days at home 30 days after index surgery due to a reduction in the length of the index hospital admission. Days at home up to 30 days may enhance the informed consent and complement traditional end points in future clinical trials. See Abstract Video. DÍAS EN CASA HASTA 30 DÍAS DESPUÉS DE LA CIRUGÍA COLORRECTAL ROBÓTICA FRENTE A LA LAPAROSCÓPICA ANTECEDENTES: «Días en el hogar hasta 30 días» es una nueva métrica de resultados centrada en el paciente que mide el número de días que los pacientes pasan en su hogar 30 días después de la cirugía. Abarca la estancia hospitalaria desde el ingreso inicial, los traslados entre hospitales y los traslados a unidades de cuidados intermedios, así como los reingresos en diferentes hospitales. OBJETIVO: Comparación de los días en casa hasta 30 días y las métricas de resultados establecidas tras la cirugía robótica frente a la cirugía laparoscópica tridimensional. DISEÑO: Estudio prospectivo de cohortes de pacientes consecutivos. ENTORNO: Hospital Universitario de Townsville y Hospital Privado Mater, Townsville, Queensland, Australia. PACIENTES: Pacientes adultos sometidos a cirugía colorrectal robótica y laparoscópica tridimensional. PRINCIPALES MEDIDAS DE RESULTADO: Días en el domicilio hasta 30 días, tasa de reingresos a los 30 días, duración de la admisión inicial y tasas de complicaciones postoperatorias a los 30 días. RESULTADOS: De los 82 pacientes, 32 (39 %) se sometieron a cirugía robótica y 50 (61 %) a cirugía colorrectal laparoscópica tridimensional. La resección anterior robótica ultrabaja y baja, así como la resección abdominoperineal, dieron lugar a un número significativamente mayor de días en el domicilio (23 frente a 15 días en el domicilio, p = 0,05) y a una menor duración de la hospitalización inicial (7 frente a 15 días en el hospital, p = 0,0003). Sin embargo, no se observaron diferencias significativas en las complicaciones postoperatorias graves ni en la tasa de reingresos a los 30 días. No se encontraron diferencias significativas entre la hemicolectomía derecha robótica y laparoscópica tridimensional, así como la resección anterior alta. LIMITACIONES: Estudio no aleatorizado. La selección de los pacientes para la cirugía robótica y laparoscópica tridimensional se realizó a criterio de los cirujanos. CONCLUSIÓN: Los pacientes sometidos a resección anterior robótica ultrabaja y baja, así como a resección abdominoperineal, pasaron más días en casa 30 días después de la cirugía índice debido a la reducción de la duración de la hospitalización índice. Los días en casa hasta 30 días pueden mejorar el consentimiento informado y complementar los criterios de valoración tradicionales en futuros ensayos clínicos. (AI-generated translation)
Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study
Kamdar, Manali , Solomon, Scott R. , Arnason, Jon , Johnston, Patrick B., Glaß, Bertram , Bachanová, Veronika , Ibrahimi, Sami , Mielke, Stephan , Mutsaers, Pim , Hernandez‐Ilizaliturri, Francisco J. , Lunning, Matthew A. , Chow, Victor A. , Montheard, Sandrine, Santamaria, Josu, Colicino, Silvia , Stepan, Lara , Izutsu, Koji , Morschhauser, Franck , Colicino, Silvia , Ogasawara, Ken , Abramson, Jeremy S , Bachanova, Veronika , Kamdar, Manali , Mielke, Stephan , Ibrahimi, Sami , Johnston, Patrick B. , Izutsu, Koji , Morschhauser, Franck , Liu, Fei‐Fei , Abramson, Jeremy S.

Journal of Clinical Oncology | July 7, 2025 | Volume: 43 | Issue: 24 | Pages: 2671-2678

10.1200/jco-25-00399 | PMID 40623279 Get It

We report 3-year follow-up results from TRANSFORM comparing lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line primary refractory/early relapsed (≤12 months) large B-cell lymphoma (LBCL). Adults eligible for autologous stem cell transplantation (N = 184) were randomly assigned 1:1 to liso-cel (100 × 10 6 chimeric antigen receptor–positive T cells) or SOC. Results are reported descriptively. With a median follow-up of 33.9 months, median (95% CI) event-free survival was 29.5 months (9.5 to not reached [NR]) for liso-cel versus 2.4 months (2.2 to 4.9) for SOC (hazard ratio [HR], 0.375; 95% CI, 0.259 to 0.542). Median progression-free survival was NR (12.6-NR) for liso-cel versus 6.2 months (4.3-8.6) for SOC (HR, 0.422; 95% CI, 0.279 to 0.639) with 36-month rates of 51% versus 26.5%. Median overall survival (OS) was NR for both arms (HR, 0.757; 95% CI, 0.481 to 1.191), with 66% of patients crossing over to receive liso-cel; 36-month OS rate was 63% for liso-cel versus 52% for SOC. OS HR (0.566 [95% CI, 0.359 to 0.895]) favored liso-cel when accounting for the treatment effect of crossover. Safety results were consistent with previous reports. At 3-year follow-up, liso-cel confirmed superior, more durable efficacy versus SOC with a favorable safety profile and no new safety signals. These data support liso-cel as an effective second-line treatment with curative potential for relapsed/refractory LBCL.
DNA2 protein destruction dictates DNA hyperexcision, cGAS–STING activation, and innate immune response in CDK12-deregulated cancers
Peng, Jiang , Wang, Zhijun , Yan, Binyuan , Zhu, Shouhai , Huang, Zhenlin , Zhang, Jianong , Ding, Donglin , Li, Xiang , Wang, Liguo , Jin, Baiye , Pang, Jun, Xia, Dan , Sun, Rui , Yan, Binyuan , Zhu, Shouhai , Wang, Liguo , Lou, Zhenkun , Jin, Baiye , Huang, Rui , Sun, Rui , Wang, Zhijun, Lou, Zhenkun , Jin, Baiye , Pang, Jun , Huang, Haojie , Sun, Rui

Proceedings of the National Academy of Sciences | July 7, 2025 | Volume: 122 | Issue: 28 | Pages: No page available

10.1073/pnas.2413732122 | PMID 40623188 Get It

CDK12 primarily functions as a transcription regulatory cyclin-dependent kinase (CDK) that controls mRNA elongation, splicing, and polyadenylation. The CDK12 gene is implicated in human cancers since it is frequently mutated and/or deleted in prostate and ovarian cancer but paradoxically amplified in breast cancer. Here, we demonstrate that CDK12 promotes serine-933 phosphorylation of DNA2, a nuclease/helicase critical for replication fork stress regulation, and the phosphorylation subsequently facilitates DNA2 polyubiquitination and degradation mediated by the APC/C CDC20 E3 ubiquitin ligase. CDK12 inactivation induces but amplification suppresses genome-wide expression of interferon response and antigen processing and presentation machinery genes in ovarian and breast cancer cells, respectively. Besides causing aberrant DNA2 stabilization, replication stress, genomic instability, and cytosolic double-stranded DNA (dsDNA) accumulation, CDK12 loss also triggers cGAS–STING activation and innate immune response, which can be reversed by forced expression of replication protein A (RPA) subunits or DNA2 depletion. Our findings identify DNA2 as a phosphorylation substrate of CDK12, connecting CDK12 to cell cycle regulation. These data also reveal DNA2 protein destruction as a critical mechanism that dictates genomic instability, cGAS–STING signaling activation, and innate immune response in CDK12-deregulated cancers.
Multilevel Intervention and Human Papillomavirus Vaccination Disparities
Jenkins, Gregory D. , Kong, Wei Yi , Rutten, Lila J. Finney , Herrin, Jeph , Sauver, Jennifer L. St. , Griffin, Joan M. , Jacobson, Robert M.

JAMA Network Open | July 7, 2025 | Volume: 8 | Issue: 7 | Pages: e2518895

10.1001/jamanetworkopen.2025.18895 | PMID 40622715 Get It

ImportanceUptake of human papillomavirus (HPV) vaccination varies by characteristics, exposing some children to higher HPV cancer risks than others.ObjectiveTo examine whether the effectiveness of a multilevel intervention on HPV vaccination differed by race and ethnicity, rurality, and Area Deprivation Index (ADI) in children ages 11 to 12 years.Design, Setting, and ParticipantsA stepped-wedge cluster randomized trial was conducted from April 2018 to August 2022 among children at 6 Mayo Clinic primary care practices in Minnesota to improve HPV vaccination. This secondary analysis was performed from March to June 2024.InterventionA multilevel intervention that included parent reminder/recall letters, which alerted parents of children due or past due for vaccination, and health care professional audit/feedback reports, which alerted health care professionals of their own vaccination rates.Main Outcome and MeasureVaccine initiation (first dose of the 2-dose HPV vaccine) and vaccine completion (second dose) were the primary study outcomes. In this secondary analysis, the effect of the intervention on HPV vaccine initiation and completion by race and ethnicity, rurality, and ADI quartiles (Qs) was assessed.ResultsA total of 6232 children aged 11 to 12 years (3285 [52.7%] male; 3481 [55.9%] aged 11 years and 2751 [44.1%] aged 12 years) were included in the analysis. Of the study participants, 304 (4.9%) were Asian, 561 (9.0%) Black, 146 (2.3%) Hispanic, 4501 (72.2%) White, and 720 (11.6%) other, including American Indian or Alaskan Native, Native Hawaiian or Pacific Islander, Other Pacific Islander, Samoan, unable to provide, unknown, chose not to disclose, or other unspecified. A total of 5434 participants (87.2%) were urban residents, and 2794 (44.8%) resided in ADI Q2 areas. With usual care, HPV vaccine initiation and completion rates were significantly lower with each increasing ADI quartile (initiation: Cochran-Armitage test for trend [SE], −0.02 [0.01]; P &amp;lt; .001; completion: Cochran-Armitage test for trend [SE], −0.05 [0.01]; P &amp;lt; .001) but did not differ by children’s race and ethnicity or rurality. With the intervention, vaccine initiation increased significantly for most children (range of rates, 9.2% [95% CI, 5.2%-13.3%] to 24.0% [95% CI, 7.5%-40.6%]) except those with Black race, in rural settings, and in ADI Q4 (highest area deprivation); vaccine completion increased significantly for most children (range of rates, 19.4% [95% CI, 5.5%-33.3%] to 31.2% [95% CI, 12.1%-50.3%]) except for those in ADI Q4.Conclusions and RelevanceIn this secondary analysis of a cluster randomized trial, a multilevel intervention was associated with increased HPV vaccination for most children but had limited effect for those residing in areas of highest deprivation. Future research should explore other intervention strategies that would effectively promote HPV vaccination among families in socioeconomically disadvantaged areas to reduce HPV vaccination disparities.Trial RegistrationClinicalTrials.gov Identifier: NCT03501992
Exogenous Hormones, Tumor Intrinsic Subtypes, and Breast Cancer
Cornet, Charlotte Le , Truong, Thérèse, Bolla, Manjeet K. , Koutros, Stella, Stone, Jennifer , Shulman, Katerina, Aronson, Kristan J. , Guénel, Pascal, Patel, Alpa V , Bodelón, Clara , Teras, Lauren R., Shahi, Shamim , Dossus, Laure, Kaaks, R., Holleczek, Bernd , Hoppe, Reiner , Czene, Kamila, Hall, P.F., Mannermaa, Arto, Wu, Anna H. , Obi, Nadia , Panayiotidis, Mihalis I. , Haiman, Christopher A., Shu, Xiao , Perou, Charles M. , Alsten, Sarah Van, Eliassen, A. Heather, Kraft, Peter, Ahearn, Thomas U., Evans, D. Gareth , Wolk, Alicja, Easton, Douglas F., Pharoah, Paul D. P., Vachon, Celine M. , Chang-Claude, Jenny, Evans, D Gareth , Perou, Charles M , Stone, Jennifer , Panayiotidis, Mihalis I , Jung, Audrey , Behrens, Sabine , Middha, Pooja , Truong, Thérèse , Jernström, Helena , Wang, Qin , Southey, Melissa C. , Freeman, Laura E. Beane , Koutros, Stella , Rennert, Gad , Murphy, Rachel A. , Guénel, Pascal , Teras, Lauren R. , Lacey, James V. , Dossus, Laure , Kaaks, Rudolf , Brenner, Hermann , Brauch, Hiltrud , Czene, Kamila, Mannermaa, Arto , Michailidou, Kyriaki , McLean, Catriona , Haiman, Christopher A., Augustinsson, Annelie , Zheng, Wei , Troester, Melissa A. , Abubakar, Mustapha , Ahearn, Thomas U., Wolk, Alicja , Milne, Roger L. , Easton, Douglas F. , Schmidt, Marjanka K. , García‐Closas, Montserrat , Vachon, Celine M. , Fortner, Renée T. , Chang‐Claude, Jenny

JAMA Network Open | July 7, 2025 | Volume: 8 | Issue: 7 | Pages: e2519236

10.1001/jamanetworkopen.2025.19236 | PMID 40622713 Get It

ImportanceEtiologic heterogeneity in breast carcinogenesis needs to be well characterized for targeted prevention. Associations between menopausal hormonal therapy (MHT) and oral contraceptive (OC) use and breast cancer intrinsic-like subtypes are not well understood.ObjectiveTo examine whether exogenous hormone use is differentially associated with breast cancer subtypes and to evaluate heterogeneity by intrinsic-like subtypes.Design, Setting, and ParticipantsThis study pooled data from 31 nested and population-based case-control studies involved in the Breast Cancer Association Consortium. The study population included individuals with breast cancer and control participants from 13 case-control studies nested in prospective cohorts (recruited between 1982 and 2011) and 18 population-based case-control studies (recruited between 1990 and 2013). Data analysis was performed in June 2024.ExposureMHT use (estrogen-progestin therapy [EPT] or estrogen-only therapy [ET]) in postmenopausal women and OC use in premenopausal women (never, past use, or current use).Main Outcomes and MeasuresBreast cancer intrinsic-like subtypes (luminal A–like, luminal B–like, luminal B–ERBB2 [formerly HER2 or HER2/neu]-like, ERBB2 enriched–like, or triple-negative) were determined by immunohistochemistry of tumor sections. Polytomous logistic regression was performed to estimate the association between exogenous hormones and risk of breast cancer by intrinsic-like subtypes. Analyses by subtypes were stratified by body mass index (BMI [calculated as weight in kilograms divided by height in meters squared]; healthy weight, 18.5-&amp;lt;25; overweight, 25-&amp;lt;30; or obesity, ≥30).ResultsThis study included 42 269 individuals with breast cancer (11 901 [28.2%] premenopausal and 30 368 [71.8%] postmenopausal; 23 353 [55.2%] had a known intrinsic-like subtype) and 71 072 control participants. The mean (SD) age of all participants was 57.9 (10.9) years. In postmenopausal women, associations between current MHT use (EPT or ET) and breast cancer differed by subtype. Current EPT users with healthy weight were more likely to be diagnosed with luminal A–like (odds ratio [OR], 2.51 [95% CI, 2.26-2.80]) or luminal B–ERBB2-like (OR, 1.95 [95% CI, 1.61-2.37]) subtypes. These associations were attenuated but remained for individuals with overweight (OR, 1.40 [95% CI, 1.02-1.92]) or obesity (OR, 1.68 [95% CI, 1.01-2.78]). EPT use increased the odds of being diagnosed with luminal B–like tumors solely in women with healthy weight (OR, 1.47 [95% CI, 1.17-1.86]). Current ET use was positively associated with luminal A–like disease in women with healthy weight only (OR, 1.16 [95% CI, 1.01-1.32]), showing inverse associations with higher BMI (obesity: OR, 0.65 [95% CI, 0.50-0.85]). In premenopausal women, recent OC use was associated with luminal B–ERBB2-like (OR, 1.50 [95% CI, 1.09-2.08]), ERBB2 enriched–like (OR, 2.33 [95% CI, 1.55-3.51]), and triple-negative (OR, 1.75 [95% CI, 1.33-2.29]; P &amp;lt; .04 for heterogeneity) tumors.Conclusions and RelevanceIn this study, clear differences were observed in associations between current EPT use and luminal-like breast cancer subtypes and other subtypes. EPT users with healthy weight were more likely to be diagnosed with luminal-like breast cancer compared with nonusers. Subtype heterogeneity was less apparent in associations of OC and ET use. Future studies on contemporary formulations, patterns of use, and routes of administration of exogenous hormone usage are warranted.